207 related articles for article (PubMed ID: 31753029)
1. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S
J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Geoerger B; Zwaan CM; Marshall LV; Michon J; Bourdeaut F; Casanova M; Corradini N; Rossato G; Farid-Kapadia M; Shemesh CS; Hutchinson KE; Donaldson F; Liao M; Caron H; Trippett T
Lancet Oncol; 2020 Jan; 21(1):134-144. PubMed ID: 31780255
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.
Shemesh CS; Chan P; Legrand FA; Shames DS; Das Thakur M; Shi J; Bailey L; Vadhavkar S; He X; Zhang W; Bruno R
Pharmacol Res Perspect; 2020 Dec; 8(6):e00685. PubMed ID: 33241650
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
Mizugaki H; Yamamoto N; Murakami H; Kenmotsu H; Fujiwara Y; Ishida Y; Kawakami T; Takahashi T
Invest New Drugs; 2016 Oct; 34(5):596-603. PubMed ID: 27363843
[TBL] [Abstract][Full Text] [Related]
5. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Felip E; Burotto M; Zvirbule Z; Herraez-Baranda LA; Chanu P; Kshirsagar S; Maiya V; Chan P; Pozzi E; Marchand M; Monchalin M; Tanaka K; Tosti N; Wang B; Restuccia E
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1142-1155. PubMed ID: 33788415
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Garralda E; Oh DY; Italiano A; Bedard PL; Delord JP; Calvo E; LoRusso P; Wainberg Z; Cervantes A; Rodriguez-Vida A; Shemesh CS; Sane R; Mendus D; Ding H; Hendricks R; Meng R; Cho BC; Kim TW; Wu B
J Clin Pharmacol; 2024 May; 64(5):544-554. PubMed ID: 38105505
[TBL] [Abstract][Full Text] [Related]
7. Model-based simulation to support the extended dosing regimens of atezolizumab.
Chou CH; Hsu LF
Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
[TBL] [Abstract][Full Text] [Related]
8. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
9. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
10. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.
Burotto M; Zvirbule Z; Mochalova A; Runglodvatana Y; Herraez-Baranda L; Liu SN; Chan P; Shearer-Kang E; Liu X; Tosti N; Zanghi JA; Leutgeb B; Felip E
Ann Oncol; 2023 Aug; 34(8):693-702. PubMed ID: 37268157
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.
Stroh M; Winter H; Marchand M; Claret L; Eppler S; Ruppel J; Abidoye O; Teng SL; Lin WT; Dayog S; Bruno R; Jin J; Girish S
Clin Pharmacol Ther; 2017 Aug; 102(2):305-312. PubMed ID: 27981577
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
14. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
Chiang AC; Sequist LVD; Gilbert J; Conkling P; Thompson D; Marcoux JP; Gettinger S; Kowanetz M; Molinero L; O'Hear C; Fassò M; Lam S; Gordon MS
Clin Lung Cancer; 2020 Sep; 21(5):455-463.e4. PubMed ID: 32586767
[TBL] [Abstract][Full Text] [Related]
15. [Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study].
Zhang L; Gong JF; Pan HM; Bai YX; Liu TS; Cheng Y; Chen YC; Huang JY; Xu TT; Ge FJ; Hsu WL; Shi J; Hu XC; Shen L
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):971-980. PubMed ID: 36241241
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
Marchand M; Zhang R; Chan P; Quarmby V; Ballinger M; Sternheim N; Wu B; Jin JY; Bruno R
Cancer Chemother Pharmacol; 2021 Aug; 88(2):211-221. PubMed ID: 33904970
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.
Dimelow R; Ji B; Struemper H
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):622-633. PubMed ID: 33245847
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
Wu B; Sternheim N; Agarwal P; Suchomel J; Vadhavkar S; Bruno R; Ballinger M; Bernaards CA; Chan P; Ruppel J; Jin J; Girish S; Joshi A; Quarmby V
Clin Transl Sci; 2022 Jan; 15(1):130-140. PubMed ID: 34432389
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
Malempati S; Weigel B; Ingle AM; Ahern CH; Carroll JM; Roberts CT; Reid JM; Schmechel S; Voss SD; Cho SY; Chen HX; Krailo MD; Adamson PC; Blaney SM
J Clin Oncol; 2012 Jan; 30(3):256-62. PubMed ID: 22184397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]